• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDTRONIC MED REL MEDTRONIC PUERTO RICO INTERSTIM II; STIMULATOR, ELECTRICAL, IMPLANTABLE, FOR INCONTINENCE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDTRONIC MED REL MEDTRONIC PUERTO RICO INTERSTIM II; STIMULATOR, ELECTRICAL, IMPLANTABLE, FOR INCONTINENCE Back to Search Results
Model Number 3058
Device Problems Energy Output Problem (1431); Patient-Device Incompatibility (2682)
Patient Problems Incontinence (1928); Pain (1994); Therapeutic Effects, Unexpected (2099); Therapeutic Response, Decreased (2271); Urinary Frequency (2275); Discomfort (2330); Complaint, Ill-Defined (2331)
Event Date 10/26/2012
Event Type  malfunction  
Manufacturer Narrative
If information is provided in the future, a supplemental report will be issued.
 
Event Description
Information was received from a healthcare provider (hcp) via a clinical study regarding a patient with an implantable neurostimulator (ins).It was reported that the patient was experiencing worsening of urinary symptoms, including urinary frequency, urge incontinence, and nocturnal enuresis.The patient was reprogrammed on (b)(6) 2013 as their symptoms continued.The patient had frequency during the daytime, about three to four hours, and twice during the night.However, it was also reported that the patient experienced incontinence at night time.The patient was not doing well, as the urinary frequency, urinary urge incontinence, and nocturnal enuresis were bad.After the ins was adjusted on (b)(6) 2013, the patient¿s urinary symptoms improved, and the outcome was considered to be resolved.It was further reported that the patient experienced vaginal pain and pressure.This would occur when the stimulation was increased to treat symptoms.When stimulation was decreased, the vaginal pain and pressure resolved but the urinary symptoms returned.Interventions included reprogramming and medication.The amplitude was decreased, the level was increased from 3 to 3.4, and vitamin a & d ointment was administered.The patient experienced continued vaginal pain with sitting after the adjustment and had mild relief with use of the ointment.It was reported that the patient was feeling slightly better on (b)(6) 2013 but the issue was not resolved.On (b)(6) 2013 it was noted that the patient was satisfied with the adjustment.It was further reported that the patient experienced a sudden onset of increased incontinence for two days, which began on (b)(6) 2013.The patient¿s symptoms were ongoing, and medication was administered on (b)(6) 2013.It was noted that the patient had an excellent response with myrebetriq.After stopping the medication and turning the ins off, the patient experienced an increase in urinary frequency/urgency.The symptoms continued because the patient would turn the ins off and on as needed due to the vaginal pain.The etiology of the event was noted as possibly related to the device or therapy and related to programming/stimulation, as the patient turned off the device and discontinued medication.The outcome of the event was noted as unresolved at the time of study closure.No further complications were reported or anticipated.Indications for use are gastrointestinal/pelvic floor and urinary dysfunction/sacral nerve stimulation.
 
Manufacturer Narrative
If information is provided in the future, a supplemental report will be issued.
 
Manufacturer Narrative
If information is provided in the future, a supplemental report will be issued.
 
Event Description
Additional information from the healthcare professional (hcp) on august 15th reported therapy resumed.The hcp noted on (b)(6) 2013 the interstim was adjusted turned off x1 then started on program 1 at 3.8 with the patient feeling sensation in the pelvis.It was noted the symptoms were ongoing on (b)(6) 2013, the patient had an excellent response to myretrio, 25 mg.Additional information from the hcp on august 15th reported the final programming date and time for the most recent interrogation prior to the event was (b)(6) 2013.There were no further complications that have been reported as a result of this event.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
INTERSTIM II
Type of Device
STIMULATOR, ELECTRICAL, IMPLANTABLE, FOR INCONTINENCE
Manufacturer (Section D)
MEDTRONIC MED REL MEDTRONIC PUERTO RICO
road 31, km. 24, hm 4
ceiba norte industrial park
juncos PR 00777
Manufacturer (Section G)
MEDTRONIC MED REL MEDTRONIC PUERTO RICO
road 31, km. 24, hm 4
ceiba norte industrial park
juncos PR 00777
Manufacturer Contact
lisa woodward clark
7000 central avenue ne rcw215
minneapolis, MN 55432
7635263920
MDR Report Key7748223
MDR Text Key116725178
Report Number3004209178-2018-17392
Device Sequence Number1
Product Code EZW
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P970004
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type consumer,health professional
Reporter Occupation Physician
Type of Report Initial,Followup,Followup
Report Date 10/03/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date02/14/2014
Device Model Number3058
Device Catalogue Number3058
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 08/01/2018
Initial Date FDA Received08/03/2018
Supplement Dates Manufacturer Received08/15/2018
08/08/2018
Supplement Dates FDA Received09/11/2018
10/02/2018
Date Device Manufactured08/20/2012
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Age89 YR
-
-